Journal of the Endocrine Society

BackgroundKidney stones, a prevalent urological disorder, are increasingly associated with potential skeletal health issues, including reduced bone mineral density (BMD) and an elevated risk of osteoporosis. However, the underlying mechanisms and subgroup-specific associations have not yet been adequately explored. MethodsThis study used data from a nationally representative survey with a weighted complex sampling design. A total of 6,464 participants were enrolled in the study. We performed weighted and unweighted comparative analyses, multivariate linear regression, mediation analysis, and subgroup evaluations to examine the association between kidney stones and BMD of the femoral neck and lumbar spine. Potential mediators, including the systemic immune-inflammation index (SII), estimated glomerular filtration rate (eGFR), and calcium-to-phosphorus (CaP) ratio, were investigated. ResultsThe presence of kidney stones was significantly associated with lower femoral neck BMD ({beta} =-0.015, p = 0.046) after adjusting for confounding factors. The CaP ratio was identified as a significant mediator (average causal mediation effect [ACME] = 0.00077, p = 0.028), whereas the SII and eGFR did not show significant mediating effects. Stratified analyses revealed stronger associations in participants aged < 50 years and in those without chronic kidney disease (CKD). No significant interactions according to gender were detected. ConclusionKidney stones are independently associated with reduced BMD, which is partially mediated by altered calcium-phosphorus homeostasis. These findings highlight the importance of monitoring bone health in patients with kidney stones, particularly in younger and non-CKD populations, and suggest that dietary mineral balance may play a critical role in bone-stone interaction.

There is an unmet need to identify biomarkers of active thyroid eye disease (TED). scRNAseq revealed that orbital fibroblasts from orbital decompressions in people with TED express high levels of thyroid hormone receptors, growth factor receptors, including insulin-like growth factor 1 receptor (IGF1R), and extracellular matrix proteins including SPARC (osteonectin), whereas orbital fat endothelial cells expressed thyroid peroxidase (TPO). SPARC was significantly raised in the serum of people with thyroid disease compared to healthy controls. Furthermore, those with moderate, severe and sight threatening TED had higher SPARC levels than those with thyroid disease but free of TED or mild TED. Free-triiodothyronine (FT3) levels were positively correlated with SPARC in moderate-sight threatening TED. SPARC and IGF1 were positively correlated across people with thyroid disease alone, as well as TED. Thyroid stimulating hormone (TSH) levels were negatively correlated with SPARC in moderate-sight threatening TED. When participants were followed longitudinally, SPARC decreased after the active phase of TED. At the protein level, immunohistochemistry indicated that SPARC was heterogeneously expressed by fibroblasts in both control and TED orbital fat. SPARC is a key mediator of fibrosis and deposition of extracellular matrix and the correlation of SPARC serum levels to TED status and FT3 make it a promising biomarker of active TED.

Menopausal hormone therapy (MHT) is prescribed for climacteric symptoms including hot flushes and weight gain and contains estrogens such as 17 beta-estradiol (17{beta}E2). However, estrogen receptor activation by MHT may increase reproductive cancers and cardiovascular event risk in some people. As the protective metabolic effects of 17{beta}E2 are partly mediated through the arcuate nucleus of the hypothalamus, restricting 17{beta}E2 actions to the brain could serve as a safer mechanism of MHT. 10{beta},17{beta}-Dihydroxyestra-1,4-dien-3-one (DHED) is a prodrug of 17{beta}E2 which is enzymatically converted to the parent hormone exclusively within the brain. DHED has demonstrated positive benefit in rodent models of centrally-mediated maladies including hot flushes, depression and cognitive decline, without peripheral hormonal burden. Therefore, we hypothesized that DHED treatment in obese female mice would act within the hypothalamus to provide the same beneficial metabolic effects as 17{beta}E2. Female mice were ovariectomized, placed on a high fat diet and split into either control, DHED, or 17{beta}E2 treatment groups. Body weight, uterus weight and glucose tolerance were recorded along with gonadal hormone receptor expression in the brain. Delivery of DHED at a similar dose as 17{beta}E2 failed to improve metabolic parameters or recapitulate the hypothalamic responses induced by 17{beta}E2. Delivery of DHED at higher doses, which elicited estrogen-like actions within the brain, still failed to improve metabolic health. Our findings suggest that peripheral actions, in addition to hypothalamic targets, may be required to mediate 17{beta}E2s protective effects on metabolism and that brain-targeted MHT may be unsuitable for improving metabolic health during menopause.

Cushings disease is caused by the overproduction of cortisol. The effects of this disease are well known in a general population, including high blood pressure, diabetes, and weight gain. Cushings disease causes both obesity and metabolic related symptoms, and it can be difficult to discern the obesity-dependent from the obesity-independent mechanisms of Cushings disease. To identify patients with Cushings disease, we identified 476 Michigan Medicine patients between January 1st 2000-2025 along with propensity-matched control cases. We stratified our participants by obesity status and into a Cushings disease group and a control group. As expected, the Cushings group had an elevated BMI compared to the control group (34 kg/m2 vs 29 kg/m2). We found a higher proportion of females diagnosed with Cushings compared to males (287 vs 72). Cushings disease was associated with an increase in the fasting glucose levels in both non-obese and obese patients. In both the obese, and non-obese patients, there was an increase in ALT and AST levels regardless of Cushings disease status, but the increase due to Cushings disease was much greater in the patients with obesity (73.4 vs 35.1 mg/dL). Cushings disease also had a moderating effect on blood pressure, with participants a BMI under 30 kg/m2 increasing by 12.6 mmHg and participants with obesity increasing by only 7.9 mmHg. These findings highlight the need to consider obesity status when evaluating the effects of Cushings disease.

Corncob bedding is commonly used for housing rodents in research, but previous work has linked corncob to altered reproductive behavior, disrupted estrous cycling, aggression, and welfare impacts across non-murine rodents. Furthermore, corncob is used as a licensed commercial rodenticide. Corncob contains endocrine-disrupting compounds (EDCs) that interfere with aromatase activity and estrogen signaling, processes critical for normal sexual behavior and development, yet effects on reproductive outcomes in mice remain unexplored. We conducted two experiments to test whether corncob bedding influences breeding performance and male sexual development. In Experiment 1, we analyzed breeding records to compare breeding performance of NSG mice housed on corncob versus cellulose bedding across two 3-month phases (N = 488 litters). Pairs housed on corncob produced significantly fewer pups than pairs housed on cellulose. To understand this effect, in Experiment 2, hormonal and morphological effects of corncob were assessed in male mice from four genetic backgrounds (C57BL/6, BALB/c, FVB, and CD1; N = 32 cages). Mice were bred and born on aspen or corncob, with half switched at weaning and half unchanged. Corncob produced timing-dependent effects in male reproductive physiology and development. Early-life corncob exposure altered baculum morphology and reduced testosterone, estradiol, and anogenital distance. In contrast, post-weaning corncob exposure resulted in hyper-masculinization, indicated by increased anogenital distance. Alongside prior evidence that corncob contains EDCs, our results raise serious concerns about its suitability as bedding in animal research. Continued use of corncob introduces uncontrolled variation that compromises animal welfare, reproduction, experimental validity, and reproducibility.

Purpose: To evaluate the efficacy and safety of oral L-ergothioneine (EGT) in improving ovarian reserve and clinical symptoms in women with diminished ovarian reserve (DOR). As a proof-ofconcept study, we explored correlations between hormonal shifts and symptom amelioration. Methods: This single-center, open-label trial enrolled 40 women (aged 35-45 years) with DOR (baseline AMH: 1.0-3.0 ng/mL) and menstrual disorders. Participants received oral EGT (120 mg/day) for three consecutive menstrual cycles. The primary outcome was the change in serum AMH. Secondary outcomes included sex hormones (FSH, E2), antral follicle count, and validated clinical questionnaires (modified Kupperman Index [KI], PSQI, SF-36, and Menstrual Symptom Score). Results: Thirty-six participants completed the intervention without product-related adverse events. EGT significantly improved core ovarian markers: mean AMH increased from 1.79 {+/-} 0.71 to 2.47 {+/-} 1.52 ng/mL (p = 0.029). Concurrently, basal FSH decreased (8.22 {+/-} 2.93 to 7.05 {+/-} 2.47 mIU/mL, p = 0.032) and E2 increased (46.00 {+/-} 22.70 to 63.46 {+/-} 50.10 pg/mL, p = 0.030). Clinical assessments showed progressive reductions in KI (5.42 {+/-} 3.66 to 1.90 {+/-} 2.16, p < 0.0001) and PSQI scores (6.89 {+/-} 1.82 to 5.50 {+/-} 1.40, p < 0.0001), alongside improved menstrual and SF-36 scores (p < 0.001). Subgroup analysis revealed upward AMH trends across both the 35-39 and 40-45 age cohorts. Crucially, endocrine restoration ({Delta}FSH) significantly correlated with improvements in sleep quality ({Delta}PSQI, r = 0.43, p < 0.05) and E2 increases (r = -0.46, p < 0.05), linking hormonal stabilization directly to systemic relief. Conclusion: Oral EGT safely enhances serum AMH and optimizes the FSH/E2 balance in women with DOR, yielding substantial relief from peri-menopausal and sleep disturbances. This pilot proofof- concept study provides the first clinical evidence supporting EGT's systemic benefits in reproductive aging, laying the groundwork for future placebo-controlled trials. Trial Registration: ChiCTR2500104484; Prospectively registered on 2025-06-18. Keywords: L-Ergothioneine, diminished ovarian reserve, anti-Mullerian hormone (AMH), oxidative stress, clinical trial

Background: A previous meta-analysis by Singh-Ospina et al. (2017) suggested that Gender affirming hormone treatment (GAHT) does not change transgender mens bone mineral density (BMD) at any clinically relevant site; emerging studies and advances in synthesis methods necessitate an updated evaluation. The primary aim was to update the bone measures of Singh-Ospina et al. (2017), with the secondary aim to expand measures to how GAHT affects musculoskeletal health. Methods: A systematic review with meta-analysis was conducted using studies published in English up to 31 July 2024, identified through three electronic databases (PubMed, Embase, SportDiscus), and final cross-referencing in summer 2025. Primary outcomes were longitudinal changes in femoral neck (FN), lumbar spine (LS), and total hip (TH) bone mineral density (BMD). Secondary outcomes included body composition and muscle strength. Standardised effect sizes (Hedges g) were pooled using the inverse heterogeneity (IVhet) model. Results: GAHT (4 years) was not associated with significant longitudinal changes in FN, LS, or TH BMD. In contrast, substantial anabolic effects were observed, including increases in BMI (g = 0.13), body mass (g = 0.18), fat-free mass (g = 0.59), and muscle strength (g = 0.86). Heterogeneity was high for muscle strength, FN and TH BMD, limiting confidence in pooled estimates. Conversely, changes in LS BMD, BMI, body mass and fat-free mass demonstrated low heterogeneity and greater consistency across studies. Conclusion: Masculinising GAHT does not negatively affect clinically relevant BMD sites while reliably increasing lean mass and muscle strength; however, the evidence base remains methodologically weak and highly variable, particularly for FN and TH. The need for continued clinical monitoring of bone health and muscle function, alongside high-quality longitudinal research incorporating advanced imaging modalities such as HR pQCT is emphasised. Strengthening the evidence base will be essential for clarifying long-term skeletal trajectories as transgender men age. PROSPERO registration: CRD42024573102

Proteomic profiling provides a framework for describing breed-specific growth, physiological and adaptive mechanisms in livestock. This study compared the plasma proteomic profiles of Red Sokoto (RS) and West African Dwarf (WAD) goats, with emphasis on growth-related proteins. Plasma samples from 20 goats (RS = 10; WAD = 10) collected across three locations in southwestern Nigeria were analysed using liquid chromatography-mass spectrometry (LC-MS). A total of 66 plasma proteins were identified in RS goats and 59 in WAD goats, of which 14 were associated with growth regulation. Distinct breed-specific expression patterns were evident. RS goats exhibited higher abundance of fibronectin and calmodulin, indicating enhanced tissue remodelling, muscle development, and calcium-mediated signaling. In contrast, WAD goats showed relatively higher expression of key metabolic and endocrine regulators, including insulin, leptin, ghrelin, glucagon, adiponectin, epidermal growth factor, erythropoietin, and thrombopoietin, reflecting greater metabolic efficiency and adaptive resilience. Gene ontology enrichment analysis revealed marked functional divergence between breeds: RS goats demonstrated stronger enrichment of GO terms related to signal transduction efficiency, cell-matrix adhesion, calcium ion binding, and growth-related morphogenetic processes, whereas WAD goats showed enrichment of GO categories associated with energy metabolism, stress adaptation, catabolic regulation, and hematopoietic support. These findings indicate that breed differences in growth potential are driven more by pathway efficiency and functional integration than hormone abundance. Plasma proteomic and GO-based functional profiles highlight coordinated anabolic and structural growth regulation in RS goats and a resilience-oriented metabolic strategy in WAD goats, with important implications for breed-specific selection, conservation, and sustainable goat production systems.

BackgroundThe tumor immune microenvironment likely plays a central role in progression of thyroid cancer. As for most other solid tumors, it is unknown if immune dysregulation contributes to earlier, subclinical stages of thyroid tumor development, or whether thyroid tumor heterogeneity might involve differential expression of pro-inflammatory mediators. MethodsThe time course of tumor-associated inflammation was studied in Tg-CreERT2;Braf CA/+ mice representing a model of BRAFV600E-driven papillary thyroid carcinoma (PTC). Tumor growth was estimated by histological examination and magnetic resonance imaging. Cytokine expression was monitored by quantitative RT-PCR, RNAScope and Western blot analyses. ResultsBased on spontaneous BrafCA activation due to leaky Cre activity in a minority of targeted cells tumors developed within a preserved thyroid tissue architecture to multifocal papillary thyroid carcinoma (PTC) over a period of 12 months. Tumorigenesis was accompanied by a gradually increased mRNA and protein expression of interleukin-1beta (IL-1{beta}), interleukin-6 and tumor necrosis factor-alpha (TNF-) starting already before Braf mutant cells commenced neoplastic growth. RNAScope revealed that both follicular cells and stromal cells expressed Il1b whereas Il6 and Tnfa transcripts were mostly confined to neoplastic epithelia. Early cytokine expression was associated with oncogene-induced senescence, whereas during tumor development (3-6 months) and in advanced tumor stages (at 12 months) the cytokine expression pattern differed among glands and tumor foci of the same gland accompanied by a highly variable locoregional lymphocytic infiltration. Oral treatment of mutant mice for 1 month with PLX4720, a vemurafenib prodrug, partially reduced cytokine expression along with inhibited tumor growth and redifferentiation of thyroid function. The magnitude of reduced cytokine expression differed much between glands and among mice of both sexes. ConclusionsThese findings indicate that oncogenic BRAFV600E targeted to the thyroid both stimulates endogenous production of IL-1{beta}, IL-6 and TNF- and recruits inflammatory cells to foci of early tumor development. PTCs of different clonal origin are distinguished by differential expression of pro-inflammatory cytokines. The anti-inflammatory effect of mutant Braf kinase inhibition varies presumably related to heterogeneous tumor development, which evolves from stochastic BrafCA activation suggesting there are clonally different probabilities of acquiring drug resistance among Braf mutant thyroid follicular cells.

Testosterone seems protective against asthma, but the underlying mechanisms are uncertain. Herein, the effect of testosterone was investigated on several features of experimental asthma. Systemic testosterone was first altered to subphysiological, physiological, or supraphysiological levels in male BALB/c mice through orchiectomy and testosterone supplementation. Testosterone (0.25 mg/day/30 g of body weight) was delivered continuously during 20 days using an implanted pump. At day 10, each group was exposed intranasally to either saline or house dust mite (HDM) once daily for 10 consecutive days to induce allergic lung inflammation. The day after the last exposure, respiratory mechanics was measured at baseline and in response to nebulized methacholine. Bronchoalveolar lavages (BAL) and lung tissues were also collected to quantify inflammation. Baseline respiratory mechanics were altered in mice with subphysiological levels of testosterone, with signs of small airway narrowing heterogeneity and closure. Testosterone drastically inhibited the HDM-induced inflammation. Yet, testosterone also increased the response to methacholine, as well as hysteresis, which are both indicators of enhanced airway smooth muscle activity. While it suggests that testosterone increases the contractility of the smooth muscle, it simultaneously and markedly inhibits inflammation. Explanations as to how these outcomes may lead to protection in asthma are discussed.

BackgroundThis study was designed to investigate the relationship between visceral fat metabolic score (METS-VF), lipid accumulation product (LAP), visceral adiposity index (VAI) and thyroid function. MethodsUtilizing data from the National Health and Nutrition Examination Survey (NHANES) 2007-2012, participants were excluded if they lacked data on METS-VF, LAP, VAI or thyroid function, or were under 18 years of age. Multiple linear regression, smooth curve fitting, and subgroup analyses were performed to determine the independent relationship between lipid accumulation and thyroid function. ResultsAfter full covariate adjustment, all three visceral adiposity indices showed significant positive associations with FT3 (LAP: {beta}=0.028, VAI: {beta}=0.024, METS-VF: {beta}=0.026; all P<0.001), FT3/FT4 ratio, TT3, TT4, and TgAb. LAP and VAI demonstrated inverse associations with FT4 ({beta}=-0.218 and -0.183, respectively; both P<0.001), while VAI and METS-VF were positively associated with TSH ({beta}=0.149, P=0.041; {beta}=0.167, P=0.025). Quartile analyses confirmed dose-dependent relationships, with Q4 participants showing elevated FT3, FT3/FT4, TT3, TT4, and reduced FT4 compared to Q1. RCS analyses revealed distinct non-linear patterns: LAP exhibited non-linearity with FT3, TSH, TT3, and TT4 (all P-nonlinear<0.05) but linear inverse associations with FT4. VAI displayed reverse L-shaped curves for FT3, TSH, and TT3 with plateaus at higher levels, while TT4 showed an inverted U-shape. METS-VF demonstrated non-linear increases for FT3 and TT3, linear associations with TSH and TT4, and an inverted U-curve for FT4. Stratified analyses identified age, race, and smoking as consistent modifiers of FT3/FT4 associations across all indices (interaction P<0.05), with stronger effects in younger/older adults, males, White participants, and high-income groups. TT3 and TT4 modification patterns varied by index. Thyroid autoantibodies showed minimal associations across all indices. ConclusionVisceral lipid accumulation is closely associated with thyroid dysfunction, and this association exhibits significant non-linear characteristics, which are modulated by factors such as age, race, and lifestyle habits. These findings provide new perspectives for the early identification and intervention of obesity-related thyroid dysfunction.

Invasive Lobular Carcinoma (ILC) is a subtype of breast cancer characterized by distinct biological features, and limited glucose uptake coupled with increased reliance on amino acid and lipid metabolism. Our prior studies highlight the importance of glutamate as a key regulator of ILC tumor growth and therapeutic response. Here we examine the expression of four key proteins involved in glutamate transport and metabolism - SLC3A2, SLC7A11, GPX4, and GLUD1/2 - in a racially diverse cohort of 72 estrogen receptor-positive (ER+) ILC and 50 ER+ invasive ductal carcinoma, no special type (IDC/NST) patients with primary disease. All four proteins associate with increased tumor size in ILC, with three showing stronger associations in Black women, but not in IDC/NST. Among these three proteins in ILC, GLUD1/2 uniquely associates with ER expression in all women, while GLUD1/2 and SLC3A2 are enriched in hypertensive women. GLUD1/2 and GPX4 are upregulated in endocrine therapy-resistant ILC cell lines, and pharmacological inhibition of GLUD1 reduces ER protein levels and cell viability. Together, these findings support a potentially important role for glutamate metabolism in ILC and suggest GLUD1 and other glutamate-handling proteins as candidate targets for therapeutic intervention in ILC.

Phthalate plasticizers are contaminants of emerging concern that interfere with the synthesis, secretion, and transport of hormones and receptors, altering the immune response and energy balance. Phthalate metabolites have been detected in marine mammals globally, and while studies on phthalate toxicity in marine mammals are beginning to emerge, a comprehensive understanding of the cellular response to these compounds remains elusive. Here, we investigated the transcriptional and bioenergetic responses to mono-ethylhexyl phthalate (MEHP), the active metabolite of di(2-ethylhexyl) phthalate (DEHP), in primary dermal derived from northern elephant seals (Mirounga angustirostris), common dolphins (Delphinus delphis), and humans. MEHP exposure did not induce cytotoxicity in any species, but triggered distinct, species-specific changes in gene expression and mitochondrial metabolism. Human cells showed the greatest transcriptional response to MEHP, upregulating detoxification, antioxidant, and inflammatory genes, and downregulating lipid metabolism pathways. Although mitochondrial respiration declined only at the highest dose, sustained extracellular acidification rates and increased glycolytic gene expression indicate a metabolic shift toward glycolysis. In contrast, elephant seal cells upregulated antioxidant and immune genes while maintaining mitochondrial respiration until the highest MEHP dose, alongside increased expression of genes involved in oxidative phosphorylation, the TCA cycle, and mitochondrial dynamics, suggesting a delayed shift to glycolysis and a potential evolutionary adaptation to sustain mitochondrial function during energy-demanding conditions such as breath-hold diving. Dolphin cells exhibited fewer transcriptional changes, which were enriched for hormone signaling and mitotic pathways, and showed dose-dependent declines in both oxygen consumption and extracellular acidification rates, even at the lowest MEHP concentration, alongside upregulation of stress and hypoxia-related genes. Together, these findings highlight distinct cellular strategies for coping with phthalate exposure and likely species-specific susceptibility to toxicant-induced stress. This study provides new insights into how marine mammals respond to plastic-derived contaminants at the cellular level, reinforcing the need for species-specific ecotoxicological risk assessments.

Oxytocin is a hypothalamic hormone and neuromodulator that has been linked to a variety of different functions, including parturition, social behavior, and cognitive processing. More recently, oxytocin has also been associated with metabolism and energy balance. However, evidence to date in this field has been inconsistent, especially in human research. To address this, we performed a preregistered systematic review and meta-analysis, which synthesized existing literature on the effect of exogenous oxytocin administration compared to a placebo on caloric intake and appetite in humans, using a living meta-analysis approach. Results indicated a significant, reductive effect of oxytocin administration on appetite in participants belonging to certain patient groups (e.g., obesity or type II diabetes; Hedges' g = -0.21). A separate moderator analysis evaluating oxytocin's effect on caloric intake revealed a conditional effect depending on the patient group, with the obesity group showing a significant effect. We did not find any statistically significant effects in healthy participants. However, further analyses revealed that these effects were also not equivalent, indicating that the data are currently too insensitive to draw clear conclusions. Taken together, the results provide some evidence for the role of oxytocin in regulating appetite in an anorexigenic, possibly homeostatic fashion. Future updates in this living meta-analysis may lead to more definitive conclusions.

Interpreting HNF1B variants is challenging in clinical practice. We aimed to integrate functional, clinical, and family data to improve variant classification, describe clinical features of carriers and report registry-level prevalence of HNF1B alterations. Clinical, genetic, and family data were analyzed from the Norwegian MODY Registry (NMR) and the Norwegian Childhood Diabetes Registry (NCDR). Clinical features of sequence variant and 17q12 deletion (17q12del) carriers were summarized, and variants were classified using ACMG-AMP-ClinGen criteria. Registry-level prevalence was reported with 95% confidence intervals. HNF1B sequence variants were functionally assessed, showing that the lower transactivation (TA) was associated with higher clinical severity. Eleven variants demonstrated impaired functional activity, with TA inversely correlated with clinical burden ({varrho} = -0.701, p = 0.002). We identified 28 individuals with 17q12del (21 in NMR, seven in NCDR) and 15 individuals carrying 14 unique (LP/P) sequence variants, all detected in the NMR. Overall, 36/486 probands (7.4%) with genetically confirmed monogenic diabetes in the NMR carried an LP/P HNF1B sequence variant or 17q12del. In the NCDR, [~] 0.2% carried 17q12del (7/3,583; 3/7 GADA/IA-2A-positive). Functional data enabled reclassification of three variants. Since many pediatric 17q12del carriers in the NMR were referred for testing due to structural renal anomalies without diabetes, HNF1B screening should be considered in children with renal/extra-renal features, irrespective of diabetes or autoantibody status. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=86 SRC="FIGDIR/small/26348894v1_ufig1.gif" ALT="Figure 1"> View larger version (24K): org.highwire.dtl.DTLVardef@41feforg.highwire.dtl.DTLVardef@ccc48borg.highwire.dtl.DTLVardef@17ba2e9org.highwire.dtl.DTLVardef@4919b_HPS_FORMAT_FIGEXP M_FIG C_FIG

BackgroundWe previously reported that extracellular vesicles derived from osteoblastic, osteoclastic, and mixed prostate cancer (PCa) cells promote osteoclast differentiation and inhibit osteoblast differentiation via the transfer of miR-92a-1-5p. However, at the same time, osteoblastic miRNAs also exist in PCa extracellular vesicles. In the present study, we focused on discovering (1) the roles of miR-375 and miR-148a-3p delivered by PCa extracellular vesicles in bone homeostasis and bone metastasis, and (2) an explanation for the co-existence of osteoblastic miRNAs and osteoclastic miRNAs in prostate cancer extracellular vesicles. MethodsConditional medium, miRNA mimics, and miRNAs overexpressed lentiviruses were employed to discover the roles of miR-375 and miR-148a-3p delivered by PCa extracellular vesicles in bone homeostasis and tumor growth. Target gene prediction and siRNAs were employed to discover the target gene(s) for miR-375 and miR-148a-3p. Droplet digital PCR (ddPCR) of the PCa extracellular vesicle miRNAs were utilized to evaluate miRNA expression at different metastatic phases. ResultsConditional medium from prostate cancer cell culture promoted osteoblast differentiation, as confirmed by ALP staining and Alizarin red staining. miR-375 and miR-148a-3p promoted osteoblast differentiation in vitro by reducing KLF4 expression, associated with increased osteoblast function as shown by ALP staining, Alizarin red staining, and Alp mRNA expression. In vivo, miR-375 and miR-148a-3p overexpressing MDA PCa 2b cells promoted osteoblastogenesis and tumor growth, which were confirmed by micro computed tomography and in vivo imaging. siRNA targeting KLF4 similarly enhanced osteoblast function and tumor cell proliferation. Based on the miRNA ddPCR data for PCa extracellular vesicles, osteoclastic and osteoblastic miRNAs existed in different bone metastatic phases. ConclusionsThese findings suggest that miR-375 and miR-148a-3p delivered by PCa extracellular vesicles regulate osteoblast function and tumor growth via targeting KLF4. Osteoclastic miR-92a-1-5p is active during the early phases of bone metastasis, while osteoblastic miR-375 and miR-148a-3p function during the late phases.

Lactation is associated with a protective effect against breast and ovarian cancer as well as against cardiovascular diseases suggesting a systemic effect. Here, we show that the serum of lactating mice and breastfeeding mothers have targeted antineoplastic effects, while serum from virgin mice and matched post-partum but non-lactating women do not. The effect is specific to cancer cells expressing Pappalysin-A (PAPP-A), a target that is shared among diseases affected by breastfeeding. RNAseq revealed that lactating serum inhibits mitochondrial function and we found that PAPP-A alone lowers mitochondrial function, suggesting that lactation serum acts by exploiting the metabolic vulnerability of these cancer cells. Using serum proteomics, we identified corticotropin release factor (CRF) as being unique to serum of lactating women and we show that CRF alone mimics the mitochondrial and anti-tumorigenic effect of lactating serum. Blocking the CRF receptor, inhibits the protective effect of lactating serum. Since CRF has shown efficacy in the clinic in other settings, our findings raise the possibility to extend its use to mimic or enhance the protective effect of breastfeeding. SummaryWe show that the serum from lactating women has anti-cancer activity and used multi-omics approaches to identify corticotropin release factor as a peptide able to mimic the effect of lactating serum by targeting cells with low mitochondrial activity.

It is now recognized that mitochondria play a crucial role in tumorigenesis, however, it has become clear that tumor metabolism varies significantly between cancer types. The failure of recent clinical trials aimed at directly targeting tumor respiration through oxidative phosphorylation inhibitors underscores the critical need for further studies providing an in-depth evaluation of mitochondrial bioenergetics. Accordingly, we comprehensively assessed the bulk tumor and mitochondrial metabolic phenotype in murine HER2-driven mammary cancer tumors and benign mammary tissue. Transcriptomic and proteomic profiling revealed a broad downregulation of mitochondrial genes/proteins in tumors, including OXPHOS subunits comprising Complexes I-IV. Despite reductions in tumor mitochondrial proteins, mitochondrial respiration was several-fold higher compared to benign mammary tissue, which persisted regardless of normalization method (wet weight, total protein content and when corrected for mitochondrial content). This upregulated respiratory capacity could not be explained by OXPHOS uncoupling, suggesting HER2 signaling regulates intrinsic mitochondrial bioenergetics. In further support, lapatinib, an EGFR/HER2 tyrosine kinase inhibitor, attenuated mitochondrial respiration in NF639 murine mammary tumor epithelial cells. Together, this data highlights that the typical correlation between mitochondrial content and respiratory capacity may not apply to all tumor types and implicates HER2-linked activation of mitochondrial respiration supporting tumorigenesis in this model.

Pacific salmon (Oncorhynchus spp.) undergo intricate physiological changes during maturation as they migrate to spawning beds and breed before succumbing to a programmed senescence (semelparous life cycle). Research into the physiological mechanisms of semelparity in salmon has identified a clear and progressive rise in sex and stress hormone levels throughout their migration, which correlates with the emergence of morphological traits, as well as changes in behavioral patterns. We examined transcriptional changes in three critical tissues (gonads, head kidney, and skeletal muscle) across the spawning migration in male and female Pink salmon (Oncorhynchus gorbuscha) to capture the molecular changes occurring in these tissues during maturation and senescence. Major transcriptional changes occurred around the time of spawning, while only modest transcriptional changes were found as the fish migrated between saltwater and freshwater. Examination of enriched biological pathways identified the signatures of semelparous catabolic processes in all tissues and a strong immune response in somatic tissues. Evidence of shifts in lipid energy mobilization were also seen in somatic tissues. A closer investigation of the expression patterns of endocrine hormone receptors showed that many endocrine pathways prioritized expression of specific dominant ohnologs to orchestrate much of the hormone response in the analyzed tissues. Our characterization of the transcriptional profiles in migrating pink salmon adds critical context to link the molecular changes occurring in tissues to the physiological transitions that define semelparous maturation in Pacific salmon. NEW & NOTEWORTHYLarge transcriptional changes occurred in the gonads, head kidney, and skeletal muscle of pink salmon during the final stages of their spawning migration. Across the tissues and sexes, spawning was marked by coordinated activation of catabolic programs (autophagy, proteolysis, cell death), and a strong immune response in somatic tissues, alongside lipid mobilization. Endocrine receptor expression analyses revealed that the response to hormones was primarily mediated by a limited number of dominant ohnologs.

The neurodevelopmental disorder Prader-Willi syndrome (PWS) is caused by loss of paternally-derived gene expression from the imprinted interval on chromosome 15q11-q13. Recently, it has been suggested that the abnormal feeding-related behaviours characteristic of PWS may be, in part, developmentally programmed in utero via abnormal placental function. Here we report that several PWS-genes are expressed in mouse placenta with marked reduced expression in a large PWS deletion mouse model (Large+/-). Moreover, expression of two PWS-transcripts, Necdin and the lncRNA Sngh14, significantly co-localises with endothelial cells in the labyrinth zone (lz) of the placenta. Critically, in the Large+/- mice, this results in a [~]25% reduction in Kdr-positive endothelial cells in the lz, although this did not directly translate into a significant reduction in fetal growth. Together these data suggest that placental function and nutrient transfer from mother to fetus may be compromised in PWS, and that the later post-natal phenotype may be partially programmed in utero. Summary statementWe systematically examine PWS-gene expression in placenta and show that incorrect expression of imprinted genes in a mouse model for PWS changes the cellular composition of the labyrinth zone.